303 related articles for article (PubMed ID: 29988102)
1. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.
Sfanos KS; Markowski MC; Peiffer LB; Ernst SE; White JR; Pienta KJ; Antonarakis ES; Ross AE
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):539-548. PubMed ID: 29988102
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients.
Daisley BA; Chanyi RM; Abdur-Rashid K; Al KF; Gibbons S; Chmiel JA; Wilcox H; Reid G; Anderson A; Dewar M; Nair SM; Chin J; Burton JP
Nat Commun; 2020 Sep; 11(1):4822. PubMed ID: 32973149
[TBL] [Abstract][Full Text] [Related]
3. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
Smith MR; Fallon MA; Goode MJ
Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
5. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
6. Current and potential targets for drug design in the androgen receptor pathway for prostate cancer.
Guddati AK
Expert Opin Drug Discov; 2018 Jun; 13(6):489-496. PubMed ID: 29621897
[TBL] [Abstract][Full Text] [Related]
7. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
Chen Y; Clegg NJ; Scher HI
Lancet Oncol; 2009 Oct; 10(10):981-91. PubMed ID: 19796750
[TBL] [Abstract][Full Text] [Related]
8. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
Culig Z; Santer FR
Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
Kim W; Jones JO; Diamond M; Haqq C; Molina A; Small EJ; Ryan CJ
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):292-9. PubMed ID: 25047002
[TBL] [Abstract][Full Text] [Related]
10. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
11. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.
Li JKM; Wang LL; Wong CYP; Chiu PKF; Teoh JYC; Kwok HSW; Leung SCH; Wong SH; Tsui SKW; Ng CF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1063-1072. PubMed ID: 33850270
[TBL] [Abstract][Full Text] [Related]
15. Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer.
Liu Y; Jiang H
Transl Androl Urol; 2020 Oct; 9(5):1937-1944. PubMed ID: 33209658
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.
Liss MA; White JR; Goros M; Gelfond J; Leach R; Johnson-Pais T; Lai Z; Rourke E; Basler J; Ankerst D; Shah DP
Eur Urol; 2018 Nov; 74(5):575-582. PubMed ID: 30007819
[TBL] [Abstract][Full Text] [Related]
17. Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab).
Peiffer LB; White JR; Jones CB; Slottke RE; Ernst SE; Moran AE; Graff JN; Sfanos KS
Neoplasia; 2022 Oct; 32():100822. PubMed ID: 35908379
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
19. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
Bryce A; Ryan CJ
Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
[TBL] [Abstract][Full Text] [Related]
20. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
